Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
CERE was delisted on the 31st of July, 2024.
0 hedge funds and large institutions have $0 invested in Cerevel Therapeutics Holdings, Inc. Common Stock in 2024 Q4 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 2 closing their positions.
100% less funds holding
Funds holding: 2 → 0 (-2)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $20.7K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IFP Advisors
Tampa,
Florida
|
-$15.5K |
| 2 |
Blue Trust Inc
Alpharetta,
Georgia
|
-$5.15K |
CERE Hedge Fund Activity: Q4 2024 in Review
0 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) for Q4 2024, worth a combined $0 — down 100% from $20.7K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of CERE and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was IFP Advisors, exiting entirely with an estimated $15.5K sold.
- 0 institutional investors held Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) as of Q4 2024, down from 2 in Q3 2024.
- Funds reported $0 of Cerevel Therapeutics Holdings, Inc. Common Stock stock for Q4 2024, down 100% quarter-over-quarter.
- 0 funds opened new Cerevel Therapeutics Holdings, Inc. Common Stock positions in Q4 2024 and 2 closed out, a net change of -2 holders.
- The largest Cerevel Therapeutics Holdings, Inc. Common Stock seller in Q4 2024 was IFP Advisors, an estimated $15.5K sold.
Based on aggregated 13F filings for Q4 2024.